An Update for NYS Healthcare Providers on COVID-19

May 27, 2021
Agenda

• Global, National, New York State Update
• COVID-19 Variants Update
• COVID-19 Vaccine Development and Safety
• Pediatric Updates on COVID-19 Vaccine
• COVID-19 Vaccine Hesitancy
• Long COVID-19
• Updated COVID-19 Guidance
• Clinician Well-being
Recordings will be available immediately:

NYSDOH COVID-19 Healthcare Provider website

In addition to YouTube, an on-demand version of our weekly sessions for healthcare providers in NYS is now available as a podcast – search NYSDOH
Disclaimer

• The situation is rapidly evolving.

• All of the information presented is based on our best knowledge as of today.
COVID-19 Global Update

Bryon Backenson
Acting Director
Division of Bureau of Communicable Diseases
# Situation Summary: COVID-19 Global, 5/25/2021


<table>
<thead>
<tr>
<th>Region</th>
<th>Confirmed Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td><strong>166,352,007</strong></td>
<td><strong>3,449,189</strong></td>
</tr>
<tr>
<td>Western Pacific</td>
<td>2,861,544</td>
<td>43,058</td>
</tr>
<tr>
<td>Europe</td>
<td>54,110,276</td>
<td>1,134,786</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>30,088,649</td>
<td>372,277</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>9,863,946</td>
<td>197,964</td>
</tr>
<tr>
<td>Africa</td>
<td>3,446,089</td>
<td>85,964</td>
</tr>
<tr>
<td>Americas</td>
<td><strong>65,980,739</strong></td>
<td><strong>1,615,127</strong></td>
</tr>
</tbody>
</table>

*Up 4.6M, Up 63K, Up 9M, Up 177K, Up 2.4M, Up 63K*
Situation Summary: COVID-19 Global, 5/25/2021
www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
Situation Summary: COVID-19 U.S. (May 26, 2021)
# NYSDOH COVID-19 Tracker (May 26, 2021)

Found at: [NYSDOH COVID-19 website](https://www.health.ny.gov/prevent/disease/communicable/covid/)

<table>
<thead>
<tr>
<th></th>
<th>Total Persons Tested</th>
<th>Total Tested Positive</th>
<th>% Positive Results</th>
<th>New Positives Today</th>
<th>Persons Tested Today</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grand Total</strong></td>
<td>55,270,938</td>
<td>2,081,049</td>
<td>3.8%</td>
<td>936</td>
<td>133,208</td>
</tr>
<tr>
<td><strong>ALL NYC</strong></td>
<td>23,756,049</td>
<td>932,354</td>
<td>3.9%</td>
<td>346</td>
<td>67,620</td>
</tr>
<tr>
<td><strong>NYS Excluding NYC</strong></td>
<td>31,514,889</td>
<td>1,148,695</td>
<td>3.6%</td>
<td>590</td>
<td>65,588</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Test Results - Yesterday</strong></th>
<th>Total Persons Tested</th>
<th>Total Tested Positive</th>
<th>% Positive, Yesterday</th>
<th>% Positive, 7 day Avg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capital Region</strong></td>
<td>4,354</td>
<td>36</td>
<td>0.8%</td>
<td>1.1%</td>
</tr>
<tr>
<td><strong>Central New York</strong></td>
<td>4,227</td>
<td>80</td>
<td>1.9%</td>
<td>1.5%</td>
</tr>
<tr>
<td><strong>Finger Lakes</strong></td>
<td>7,215</td>
<td>119</td>
<td>1.6%</td>
<td>2.2%</td>
</tr>
<tr>
<td><strong>Long Island</strong></td>
<td>16,181</td>
<td>98</td>
<td>0.6%</td>
<td>0.7%</td>
</tr>
<tr>
<td><strong>Mid-Hudson</strong></td>
<td>12,628</td>
<td>80</td>
<td>0.6%</td>
<td>0.8%</td>
</tr>
<tr>
<td><strong>Mohawk Valley</strong></td>
<td>3,050</td>
<td>35</td>
<td>1.1%</td>
<td>1.0%</td>
</tr>
<tr>
<td><strong>New York City</strong></td>
<td>67,620</td>
<td>346</td>
<td>0.5%</td>
<td>0.6%</td>
</tr>
<tr>
<td><strong>North Country</strong></td>
<td>2,083</td>
<td>17</td>
<td>0.8%</td>
<td>1.2%</td>
</tr>
<tr>
<td><strong>Southern Tier</strong></td>
<td>8,753</td>
<td>31</td>
<td>0.4%</td>
<td>0.6%</td>
</tr>
<tr>
<td><strong>Western New York</strong></td>
<td>7,097</td>
<td>94</td>
<td>1.3%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>
COVID-19 Variants Update
## SARS-CoV-2 Variants of Interest/Concern in NY, GISAID pull, 5/24/22

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital District</td>
<td>121</td>
<td>56</td>
<td>37</td>
<td>5</td>
<td>16</td>
<td>0</td>
<td>16</td>
<td>1</td>
<td>5</td>
<td>3</td>
<td>1236</td>
</tr>
<tr>
<td>Central</td>
<td>132</td>
<td>19</td>
<td>13</td>
<td>5</td>
<td>7</td>
<td>1</td>
<td>3</td>
<td>13</td>
<td>4</td>
<td>0</td>
<td>568</td>
</tr>
<tr>
<td>Finger Lakes</td>
<td>341</td>
<td>17</td>
<td>12</td>
<td>16</td>
<td>8</td>
<td>0</td>
<td>1</td>
<td>22</td>
<td>4</td>
<td>0</td>
<td>1212</td>
</tr>
<tr>
<td>Long Island</td>
<td>367</td>
<td>208</td>
<td>139</td>
<td>61</td>
<td>96</td>
<td>3</td>
<td>16</td>
<td>12</td>
<td>27</td>
<td>0</td>
<td>2024</td>
</tr>
<tr>
<td>Mid-Hudson</td>
<td>192</td>
<td>191</td>
<td>128</td>
<td>63</td>
<td>108</td>
<td>0</td>
<td>11</td>
<td>8</td>
<td>8</td>
<td>0</td>
<td>1624</td>
</tr>
<tr>
<td>Mohawk Valley</td>
<td>17</td>
<td>9</td>
<td>9</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>15</td>
<td>1</td>
<td>0</td>
<td>517</td>
</tr>
<tr>
<td>New York City</td>
<td>4728</td>
<td>5302</td>
<td>4248</td>
<td>1570</td>
<td>2145</td>
<td>38</td>
<td>291</td>
<td>147</td>
<td>279</td>
<td>63</td>
<td>25167</td>
</tr>
<tr>
<td>New York</td>
<td>2036</td>
<td>1078</td>
<td>758</td>
<td>291</td>
<td>382</td>
<td>14</td>
<td>112</td>
<td>132</td>
<td>110</td>
<td>12</td>
<td>7021</td>
</tr>
<tr>
<td>Unknown</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>170</td>
</tr>
<tr>
<td>North Country</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>88</td>
</tr>
<tr>
<td>Out-of-State</td>
<td>60</td>
<td>19</td>
<td>6</td>
<td>25</td>
<td>13</td>
<td>0</td>
<td>1</td>
<td>5</td>
<td>8</td>
<td>0</td>
<td>605</td>
</tr>
<tr>
<td>Southern Tier</td>
<td>134</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>17</td>
<td>1</td>
<td>77</td>
<td>7</td>
<td>0</td>
<td>1181</td>
</tr>
<tr>
<td>Western</td>
<td>8131</td>
<td>6908</td>
<td>5356</td>
<td>2044</td>
<td>2784</td>
<td>73</td>
<td>452</td>
<td>432</td>
<td>454</td>
<td>78</td>
<td>41413</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>8131</td>
<td>6908</td>
<td>5356</td>
<td>2044</td>
<td>2784</td>
<td>73</td>
<td>452</td>
<td>432</td>
<td>454</td>
<td>78</td>
<td>41413</td>
</tr>
</tbody>
</table>
COVID-19 Vaccine Development and COVID-19 Vaccine Safety

Elizabeth Rausch-Phung, MD, MPH
Medical Director
NYSDOH Bureau of Immunization
How were COVID-19 Vaccines Developed So Quickly? (Slide 1/2)

- **Did not start from scratch**: Vaccine candidates were previously developed and studied against:
  - SARS-CoV-1 (which caused the 2003 SARS outbreak) and
  - MERS-CoV (which caused the 2013 Middle Eastern Respiratory Syndrome outbreak).

- **Data transparency**: The SARS-CoV-2 genetic code was rapidly shared with scientists across the globe in early 2020.

- **High rates of COVID-19 infections**: Researchers study vaccine effectiveness by comparing the number of infections in people who got the vaccine vs. people who did not.
  - Vaccines against rare diseases need to be studied for many years before there are enough infections to measure effectiveness.
  - High prevalence of COVID-19 in 2020 meant that researchers had enough data sooner than usual.
How were COVID-19 Vaccines Developed So Quickly? (Slide 2/2)

- **Up-front investment in manufacturing**: U.S. government invested in factories and supplies to make and distribute vaccines before the clinical trials were even done.
  - This step usually isn’t done until after a vaccine has been approved.

- **Combined phases of clinical trials**: Some vaccines had combined Phase 1/2 studies; others combined Phases 2 and 3.
  - Combined phases were done simultaneously but included all of the steps of solo phases.
COVID-19 Messenger RNA (mRNA)-Based Vaccines

- Use the process that cells use to make proteins in order to cause an immune response against the spike protein of the SARS-CoV-2 virus
- Genetic material from the vaccine never enters the nucleus of the cell and does not affect or interact with a person’s DNA
- mRNA is then broken down and naturally cleared by the human body
- mRNA technology is new, but not unknown, and has been studied for more than a decade
- Do not contain a live virus and do not cause COVID-19 infection
- U.S. COVID-19 mRNA vaccines
  - Pfizer-BioNTech – EUA authorized 12/11/2020
  - Moderna – EUA authorized 12/18/2020
Pfizer-BioNTech and Moderna COVID-19 Vaccine Efficacy

- Pfizer-BioNTech COVID-19 vaccine efficacy **95%** after receipt of 2 doses
  - Consistent across age, gender, race, ethnicity and prior COVID-19 infection
- Moderna vaccine efficacy **94.1%** starting 2 weeks after the second dose
  - Consistent across age, race, ethnicity and gender groups
- Both vaccines estimated 100% effective in prevention of severe cases
- CDC “real world” vaccine efficacy study
  - 1 dose of either Pfizer or Moderna COVID-19 vaccine 82% effective against symptomatic COVID-19
  - 2 doses **94%** effective

COVID-19 Adenovirus-Vectored Vaccines

- Use a genetically modified and weakened adenovirus to carry the genes encoding the SARS-CoV-2 spike protein
- Similar to the mRNA vaccines, vaccinated individuals develop immune responses to the spike protein
- U.S. COVID-19 vaccine candidates
  - Janssen (Johnson & Johnson) – EUA authorized 2/27/2021
  - AstraZeneca – in Phase 3 Clinical trials
Janssen COVID-19 Vaccine Efficacy

• 67% effective in preventing moderate-to-severe symptomatic COVID-19 at 14 days after vaccination
  o Greater efficacy observed in U.S. clinical trials (74%) compared with Brazil (66%) or South Africa (52%)

• 85% effective in preventing severe/critical COVID-19 at 28 days post-vaccination
  o Similar efficacy across all locations studied

• Up to 100% effective in preventing COVID-19 requiring hospitalization at least 28 days post-vaccination

https://www.fda.gov/media/146304/download
## Early Release

**TABLE 2.** Percentage of v-safe enrollees who completed at least one survey (N = 1,602,065) with local and systemic reactions reported for day 0–7 and for day 1 after receiving Pfizer-BioNTech and Moderna COVID-19 vaccines — v-safe,* United States, December 14, 2020–January 13, 2021

<table>
<thead>
<tr>
<th>Local and systemic reaction</th>
<th>Both vaccines</th>
<th>Pfizer-BioNTech vaccine</th>
<th>Moderna vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 0–7</td>
<td>Dose 1, day 1</td>
<td>Dose 2, day 1</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>70.9</td>
<td>72.9</td>
<td>79.3</td>
</tr>
<tr>
<td>Fatigue</td>
<td>33.5</td>
<td>21.9</td>
<td>53.5</td>
</tr>
<tr>
<td>Headache</td>
<td>29.5</td>
<td>17.5</td>
<td>43.4</td>
</tr>
<tr>
<td>Myalgia</td>
<td>22.9</td>
<td>14.7</td>
<td>47.2</td>
</tr>
<tr>
<td>Chills</td>
<td>11.6</td>
<td>5.5</td>
<td>30.6</td>
</tr>
<tr>
<td>Fever</td>
<td>11.4</td>
<td>5.8</td>
<td>29.2</td>
</tr>
<tr>
<td>Injection site swelling</td>
<td>10.8</td>
<td>6.2</td>
<td>8.6</td>
</tr>
<tr>
<td>Joint pain</td>
<td>10.4</td>
<td>5.3</td>
<td>23.5</td>
</tr>
<tr>
<td>Nausea</td>
<td>8.9</td>
<td>4.2</td>
<td>14.0</td>
</tr>
</tbody>
</table>


• Active surveillance of post-vaccination events among pregnant persons using the v-safe pregnancy registry
• Frequency of adverse pregnancy and neonatal outcomes among COVID-19 vaccine recipients were similar to baseline rates
• Pregnant vaccine recipients had similar adverse reactions as non-pregnant recipients, aside from higher rates of nausea and vomiting
Contact Information

- New York State Department of Health, Bureau of Immunization
- (518) 473-4437
- covid19vaccine@health.ny.gov
- NYSDOH COVID-19 hotline 1-888-364-3065
COVID-19 Clinical Updates
May 27, 2021

Jessica Kumar DO, MPH
Medical Director
Bureau of Communicable Disease Control
Agenda

- Pediatric updates on COVID-19 vaccine
- Mask guidance in preschool/daycare
- Education about vaccine hesitancy
- Long COVID update
Moderna (mRNA-1273) Pediatrics Trials: KidCOVE

Phase 2/3 Clinical trials with NIH/BARDA

- Ages 6 months to 12 years
- 6,750 healthy children
- Participants ages 2 to 12 years will receive the first dose of the mRNA vaccine at 50 µg or 100 µg
- Participants ages 6 months and 2 years will receive the first of three doses at either 25 µg, 50 µg or 100 µg
- Outcome measures include a correlate of protection, or through “immunobridging” the population aged 18 to 25 years

Phase 3 COVE study of mRNA-1273 in adults ages 18 and above [Link]
mRNA-1273 Phase 3 Sites in NY: Meridian Clinical Research Center in Binghamton, Weill Cornell Chelsea and Weill Cornell Medical College
Pfizer Pediatric Trials

• Phase 1/2/3 study of BNT162b2 in children aged 6 months to 11 years
• The study will plan to enroll over 4,600 participants
• Two-dose schedule (approximately 21 days apart) in three age groups: children aged 5 to 11 years, 2 to 5 years, and 6 months to 2 years
• Link to Pfizer pediatric trials
• Recruitment site for the Pfizer trial Link
Pediatric Mask Updates

YouTube Video from the American Academy of Pediatrics: https://youtu.be/05FEAJh_tNE
Kids and Mask Changes

As of 5/24, New York State Office of Children and Family Services and the Department of Health, guidance has been revised for childcare programs

Masks for children ages 2-5 are **encouraged**, not required to wear masks

NY Forward Guidance [Link](#)

NYS/OCSF guidance [Link](#)

- CDC K-12 reopening guidance [Link](#)
- CDC Science Brief on Cloth Masks [Link](#)
- MMWR on Transmission in Schools in Georgia [Link](#)
- MMWR on testing in schools [Link](#)
- American Academy of Pediatrics Masking Guidance for Children: [Link](#) Brief [Link](#)
Vaccine Confidence

https://www.cdc.gov/vaccines/ed/youcalltheshots.html
Messaging

- The right message from the right source
- Safety and efficacy
- Listen and answer questions
- Fully vaccinated people no longer need to wear a mask or physically distance in any setting, except where required by federal, state, local, tribal, or territorial laws, rules, and regulations, including local business and workplace guidance
- Fully vaccinated people can refrain from testing following a known exposure unless they are residents or employees of a correctional or detention facility or a homeless shelter
- CDC Link
CDC/AAP resources for children and adolescents

- Pediatric health care provider tool kit [Link]: fact sheets, stickers, graphics, answering parent/guardian questions
- Child/Adolescent patient handout [Link]
- Empowering health care providers to communicate about vaccines [Link]
- Practice implementation for states [Link]
- Focus on rural/poor access areas [Link]
- AAP recommends the covid vaccine and support co-administration [Link]

Vaccine Groups for Families/Parents
- Voices for vaccines: [https://www.voicesforvaccines.org/](https://www.voicesforvaccines.org/)
- Parents Together: [https://parentstogetheraction.org/](https://parentstogetheraction.org/)
- Vaccinate your Family: [https://vaccinateyourfamily.org/](https://vaccinateyourfamily.org/)
- Young Invincibles: [https://younginvincibles.org/](https://younginvincibles.org/)
New Specific Resources

Links for children and adolescents

- COVID Community Corp [Link]
- Vaccine Tool kit for children and adolescents [Link]
- Myth busting [Link]
- National Foundation for Infectious Diseases Resource for vaccines communication [Link]
- Addressing Racial Disparities [Link]

- Center for Medicare/Medicaid or CMS resource for vaccine confidence [Link to ppt] and [Link to recording]
- Future and past trainings from CMS: [Link]
- Made To Save [Link]
- This is Our Shot [Link]
Vaccinate with Confidence: Be a vaccine champion

• Becoming a COVID vaccinator presented by the AAP [Link]
• CDC COVID-19 Vaccine Task Force staff may be deployed to provide in-person support
• Request a consult: [Link] to form
• If you have questions about this process, please email confidenceconsults@cdc.gov
• Vaccine confidence resources [link]
• Vaccinate with Confidence [link]

The Journey to Vaccination

- Knowledge Awareness & Beliefs
- Preparation Cost & Effort
- Point of Service
- Experience of Care
- After Service
Post-COVID/Long COVID-19 Updates
Post COVID Conditions

- Post-acute COVID-19, long-term effects of COVID, long COVID, post-acute COVID syndrome, chronic COVID, long-haul COVID or late sequelae
- Post-COVID conditions refer to the wide range of physical and mental health consequences experienced by some patients that are present four or more weeks after SARS-CoV-2 infection, including by patients who had initial mild or asymptomatic acute infection
- Symptoms may include cognitive difficulties, fatigue, headache, dyspnea, and palpitations
- Evaluating and Treating post COVID conditions [Link] call on Thursday, June 3, 2021, 2:00 PM – 3:00 PM ET
- CDC resource [Link]
- Clinical call originally presented in Jan [Link]
Ongoing studies

- WHO case report form for post COVID conditions [Link]
- SARS-CoV-2 Recovery Cohort through NIH which aims to provide more insight into why some patients develop Long COVID and how best to manage it [Link]
- NIH launches new initiative to study “Long COVID”. Updated February 23, 2021 [Link]
- Are vaccines safe in patients with Long COVID? A prospective observational study [Link]
- Resource for patients: https://www.survivorcorps.com/pccc
COVID complications in children post MIS-C

- Multisystem inflammatory syndrome in children (MIS-C)
- In a small (n=46) retrospective cohort study symptoms improved in approximately 6 months
- By 6 months, systemic inflammation was resolved in all but one patient
- 38 (90%) of 42 patients who had positive SARS-CoV-2 IgG antibodies within 6 weeks of admission remained seropositive at 6 months
- Echocardiograms were normal in 44 (96%) of 46 patients by 6 months
- Gastrointestinal symptoms that were reported in 45 (98%) of 46 patients at onset were present in only six (13%) of 46 patients at 6 months
- Renal, hematological, and otolaryngological symptoms resolved by 6 months
- 45 (98%) of 46 patients were back in full-time education (virtually or face to face) by 6 months.
- Lancet study Link
FDA Updates
FDA update

The FDA issued a reminder to health care providers to give clear, step-by-step instructions to patients who, in a health care setting, self-collect anterior nasal samples for SARS-CoV-2 testing. Without proper instructions, patients may not collect an adequate sample for testing, which may decrease the sensitivity of the test.

The FDA issued a safety communication to remind health care providers and the public that results from currently authorized SARS-CoV-2 antibody tests should not be used to evaluate a person’s level of immunity or protection from COVID-19 at any time, and especially after the person received a COVID-19 vaccination.

The FDA updated the definition of high risk for COVID-19 to include additional medical conditions and factors associated with increased risk for progression to severe disease. This update applies to the emergency use authorizations (EUAs) for REGEN-COV (Casirivimab and Imdevimab) and Bamlanivimab and Etesevimab.

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progressing to severe COVID-19 and authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed above.

Fact Sheet for Health Care Providers for Bamlanivimab and Etesevimab
Fact Sheet for Health Care Providers for REGEN-COV (casirivimab with imdevimab)

Guidance Updates
Guidance update

5/24/21 Interim guidance for child care, day camp, overnight camps during the COVID-19 public health emergency:

• applies to both regulated and unregulated programs for children
• guidelines are minimum requirements only and the owner/operator of any child care, day camp, or overnight camp program is free to provide additional precautions or increased restrictions.

Physical Distancing:
Social distancing and face covering requirements do not apply to those who are fully vaccinated except as otherwise specified in this document

Guidance update cont.

5/24/21 Interim guidance for child care, day camp, overnight camps during the COVID-19 public health emergency:

Masks:
Responsible Parties should **encourage** that children/campers age 2 and older who are not fully vaccinated wear face coverings except when eating, drinking, showering, swimming, or sleeping/resting.

Children/campers **may also remove face coverings outdoors** when they are unable to tolerate a face covering for the physical activity. Face coverings must be worn by individuals who are not fully vaccinated during transportation.

COVID-19 Antigen Testing FAQ


Information on:

• SARS-CoV-2 antigen tests that are currently authorized for use
• Testing in symptomatic and asymptomatic individuals
• SARS-CoV-2 POC antigen tests to be used for both diagnostic testing and screening testing

https://coronavirus.health.ny.gov/covid-19-testing
Clinician Well-being

Louis S. Snitkoff, MD, MACP
Immediate Past-President
American College of Physicians, NY Chapter
COVID-19 Resources
What is the Provider Compilation Document?

- Contains links to the most recently available COVID-19 guidance for healthcare providers
- Includes links and guidance for:
  - Vaccinations, testing, quarantine, infection control and other relevant information for outpatient healthcare providers
- Updated weekly or as new guidance is released
COVID-19 Healthcare Provider Compilation

- Link on NYSDOH web page: https://coronavirus.health.ny.gov/information-healthcare-providers

Information for Healthcare Providers

Providing up-to-date information about the COVID-19 outbreak for NYS healthcare providers, including:

- COVID-19 Vaccine Information for Providers
- Weekly health care provider updates
- COVID-19 webinars, health advisories, printable materials and guidance
- COVID-19 Testing Information
- Joining the NYS health care provider reserve workforce
- Creating a Health Commerce Account

For questions, contact covidproviderinfo@health.ny.gov
# NYSDOH COVID-19 Healthcare Provider Compilation

As of February 4, 2021, 9:00 AM

The information in this compilation is current only as of the above date and time.

**Purpose:** The purpose of this publication is to provide healthcare providers in New York State with a consolidated reference document of guidance released by the New York State Department of Health (NYSDOH) related to the COVID-19 pandemic response. This document displays hyperlinks to the current guidance documents. Additional COVID-19 resources may be found on the NYSDOH Information for Healthcare Providers webpage. Recordings of COVID-19 Weekly Healthcare Provider Updates are also available on the NYSDOH webpage.

## COVID-19 Vaccine Information for Providers

<table>
<thead>
<tr>
<th>Link to Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NYSDOH COVID-19 Vaccine Webpage</strong></td>
</tr>
<tr>
<td>• How to Order COVID-19 Vaccine</td>
</tr>
<tr>
<td>• Documents and Guidance on Administering the COVID-19 Vaccine and Vaccine Prioritization</td>
</tr>
<tr>
<td>• Provider Training</td>
</tr>
<tr>
<td><strong>Determine Eligibility for a Vaccine and Find a Local Vaccination Site to Make an Appointment</strong></td>
</tr>
</tbody>
</table>

## Testing and Specimen Collection

<table>
<thead>
<tr>
<th>Link to Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NYSDOH COVID-19 Testing Webpage</strong></td>
</tr>
<tr>
<td>• Antigen Testing</td>
</tr>
<tr>
<td>• Antibody Testing</td>
</tr>
<tr>
<td>• Molecular Testing</td>
</tr>
<tr>
<td>• Protocols for Drive-Through Testing</td>
</tr>
<tr>
<td><strong>DOM Hudson Health Center Coronavirus Testing Guidance Webpage</strong></td>
</tr>
<tr>
<td>• Specimen Collection, Handling and Transport</td>
</tr>
<tr>
<td>• Guidance on Pooling</td>
</tr>
<tr>
<td>• Test Results Reporting</td>
</tr>
<tr>
<td>• Infectious Disease Reporting</td>
</tr>
</tbody>
</table>

## Quarantine, Travel and Exposure

<table>
<thead>
<tr>
<th>Link to Guidance</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COVID-19 Travel Advisory Webpage</strong></td>
<td></td>
</tr>
<tr>
<td>Guidance on Use Of COVID-19 Sick Leave</td>
<td>01/20/21</td>
</tr>
<tr>
<td>UPDATE to Health Advisory: Revised Protocols for Personnel in Healthcare and Other Direct Care Settings to Return to Work Following COVID-19 Exposure</td>
<td>04/07/21</td>
</tr>
<tr>
<td>Quarantine for persons exposed to COVID-19</td>
<td>12/26/20</td>
</tr>
<tr>
<td>Interim Guidance for Individuals Traveling To New York State for Medical Treatment</td>
<td>11/09/20</td>
</tr>
<tr>
<td>NYS DOH and NYS DOH Guidance on Use of COVID-19 Sick Leave for Health Care Employers</td>
<td>06/25/20</td>
</tr>
<tr>
<td>Symptom-Based Strategy to Discontinue Home Isolation for Persons with COVID-19</td>
<td>05/30/20</td>
</tr>
<tr>
<td>Contact Tracing Tool for People Being Tested for COVID-19</td>
<td>05/14/20</td>
</tr>
</tbody>
</table>
NY State DOH COVID-19 Hotline

Call the Hotline: 1-888-364-3065 or Ask a Question

New Yorkers Can Now Report Vaccine-Related Fraud by Calling 833-VAX-SCAM (833-829-7226) or Emailing STOPVAXFRAUD@health.ny.gov
COVID Alert NY is a voluntary, anonymous, exposure-notification smartphone app.

You will get an alert if you were in close contact with someone who tests positive for COVID-19.

Knowing about a potential exposure allows you to self-quarantine immediately, get tested and reduce the potential exposure risk to your family, friends, neighbors, co-workers and others.

The more people who download COVID Alert NY, the more effective it will be.

Help protect your community while maintaining your privacy.

The free mobile apps—available to anyone 18 or older who lives, works, or attends college in New York or New Jersey—are available for download from the Google Play Store or Apple App Store. COVID Alert NY is available in English, Spanish, Chinese, Bengali, Korean, Russian and Haitian Creole.

Download the free app to your smartphone to receive an alert if you have been in close contact with someone who has tested positive for COVID-19.
Healthcare Provider Well-Being
Healthcare Provider/Physician Wellness

Supporting Healthcare Provider Well-Being in COVID & Beyond

July 9, 2020

Howard Zucker, MD, JD
Commissioner of Health, New York State

https://www.youtube.com/watch?v=B9PRLV-_XQE
Mental Health Resources

• NYS Mental Health Helpline
  1-844-863-9314

• The helpline is staffed by specially trained volunteers, including mental health professionals, who have received training in crisis counseling related to mental health consequences of infectious disease outbreaks, typical stress reactions, anxiety management, coping skills, and telephonic counseling
Healthcare Provider/Physician Wellness

- The state is partnering with the Kate Spade New York Foundation and Crisis Text Line to provide a 24/7 emotional support service for frontline healthcare workers
- **Text NYFRONTLINE to 741-741** to access these emotional support services
- New York State-regulated health insurers will be required to waive cost-sharing, including deductibles, copayments and coinsurance, for in-network mental health services for frontline essential workers during COVID-19
Mental Health Resources

COVID-19 Resources

The COVID-19 pandemic has left many New Yorkers feeling anxious and stressed.

Learn more about:
- The COVID-19 Vaccine
- Managing anxiety in difficult times
- Coronavirus-related guidance for healthcare providers
- How you can help

VACCINATION INFORMATION

New York State COVID-19 Vaccine webpage
Learn more about the State’s distribution plan and if you’re eligible for the vaccine.

OMH COVID-19 Vaccine Fact Sheet
Get answers to common questions about the COVID-19 Vaccine.

PUBLIC RESOURCES

NY Project Hope Emotional Support Helpline: 1-844-863-9314
New York has a free, confidential helpline as part of the FEMA response to COVID-19. Call 1-844-863-9314 or visit nyprojecthope.org.

Tips for Mental Wellness
- How to manage COVID-related stress and anxiety
- Mental Health in the Next Phase of Coronavirus
- A guide of coping tips and resources to help with the ongoing mental health impact of the pandemic
- Mental Health Resources During an Emergency
- People often experience anxiety, fear, and helplessness during an emergency. Know the signs and get help.

https://omh.ny.gov/omhweb/covid-19-resources.html
Are you struggling with everyday life stressors?

MSSNY’s P2P Supporters are here to help

Any physician, resident or medical student who wishes to relate to a peer supporter may contact the Medical Society of the State of New York in the following ways:

- Email: P2P@mssny.org
- Phone 1-844-P2P-PEER (1-844-727-7337)

Support, Empathy & Perspective
CDC COVID-19 Website

Additional COVID-19 Resources
NYS resources

- [https://forward.ny.gov/early-warning-monitoring-dashboard](https://forward.ny.gov/early-warning-monitoring-dashboard)
- Testing/tracing
- New infections/severity based on hospitalization
- Hospital capacity
Helpful Links

• [HERO Together: COVID vaccine effects study](#)
• [New York State vaccine tracker](#)
• [NY Times vaccine tracker](#)
Highlighted CDC resources

- **Update to COVID-19 clinical considerations:** [www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html](http://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html)

- **Nursing Home COVID-19 Data Dashboard:** CDC’s National Healthcare Safety Network (NHSN) is supporting the nation’s COVID-19 response by providing a Long-term Care Facilities (LTCFs) COVID-19 Module, [NHSN Nursing Home COVID-19 Data Dashboard](https://www.cdc.gov/nhsn/)

- **Estimated Disease Burden of COVID-19:** estimates of COVID-19 infections, symptomatic illnesses, and hospitalizations using a statistical model to adjust for cases that national surveillance networks are unable to capture for a number of reasons.

- These estimates and methodology used to calculate them are published in *Clinical Infectious Diseases* and available [online](https://wwwnc.cdc.gov/eid). To learn more, please visit: [Estimated COVID-19 Burden](https://www.cdc.gov/covid19/clinical-guidance/burden.html)
NYS Medicaid Telehealth Updates and Guidance

NYSDOH COVID-19 Guidance for Medicaid Providers website

- **Webinar**: New York State Medicaid Guidance Regarding Telehealth, Including Telephonic, Services During the COVID-19 Emergency - 5.5.2020
  - Slides (PDF)
  - Recording *Coming Soon*

- **Frequently Asked Questions (FAQs)** on Medicaid Telehealth Guidance during the Coronavirus Disease 2019 (COVID-19) State of Emergency - [Web](#) - [PDF](#) - *Updated 5.1.2020*
Telehealth Guidance

- American College of Physicians Telehealth Resource:
  www.acponline.org/practice-resources/business-resources/health-information-technology/telehealth

- CDC Outpatient and Ambulatory Care Setting Guidance:

- Medicaid:
  www.health.ny.gov/health_care/medicaid/program/update/2020/
NYSDOH COVID-19 Website

LAST UPDATED: JANUARY 13, 2021 AT 2:30 PM

What You Need to Know

- Visit ny.gov/vaccine to get the facts on the COVID-19 Vaccine in New York.
- The COVID-19 Emergency Eviction and Foreclosure Prevention Act places a moratorium on residential evictions until May 1, 2021 for tenants who have endured COVID-related hardship.
- A new Micro-Cluster Strategy is addressing COVID-19 hot spots that have cropped up across the state.
  - Look up an address to see if falls into a Red, Orange, or Yellow Zone
  - See the restrictions that correspond to each color-coded level of cluster zone
- Indoor and outdoor gatherings at private residences are limited to no more than 10 people.
- Read New York's COVID-19 Winter Plan to mitigate the spread of the virus and bolster New York’s hospital’s preparedness.
- New travel guidelines are in effect that allow out-of-state travelers to “test out” of the mandatory 10-day quarantine.
- To report violations of health and safety restrictions and requirements for businesses, gatherings and individuals, please choose the appropriate link below:
  - File a complaint about a business, location or incident in your community.
  - File a complaint against your employer or place of work.
- Health care workers can text NYFRONTLINE to 741-741 to access 24/7 emotional support services. Any New Yorker can call the COVID-19 Emotional Support Hotline at 1-844-863-9314 for mental health counseling.

https://coronavirus.health.ny.gov/home
NYSDOH COVID-19 Website

<table>
<thead>
<tr>
<th>Schools</th>
<th>Mental Health Resources</th>
<th>Mandatory and Precautionary Quarantine</th>
<th>Seasonal Celebrations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare Providers</td>
<td>Long-Term Care Facilities</td>
<td>Childcare Providers</td>
<td></td>
</tr>
<tr>
<td>Movie Theaters</td>
<td>Ski Facilities</td>
<td>Pregnancy Guidelines</td>
<td></td>
</tr>
<tr>
<td>Employees &amp; Employers</td>
<td>Insurance</td>
<td>Cyber Security</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Price Gouging</td>
<td></td>
</tr>
</tbody>
</table>

https://coronavirus.health.ny.gov/home
NYSDOH COVID-19 Testing Website

https://coronavirus.health.ny.gov/covid-19-testing
Mirror Clings

To order mirror clings for public use email the NYSDOH:

bmcc@health.ny.gov
QUESTIONS?

TO NYS HEALTHCARE PROVIDERS

THANK YOU!